Cargando…

Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care

Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21(st) century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Anthony George, Hongaard-Andersen, Peter, Moscicki, Richard A., Sahakian, Barbara, Quirion, Rémi, Krishnan, K. Ranga Rama, Race, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360252/
https://www.ncbi.nlm.nih.gov/pubmed/25542690
http://dx.doi.org/10.1093/ijnp/pyu100
_version_ 1782361524022542336
author Phillips, Anthony George
Hongaard-Andersen, Peter
Moscicki, Richard A.
Sahakian, Barbara
Quirion, Rémi
Krishnan, K. Ranga Rama
Race, Tim
author_facet Phillips, Anthony George
Hongaard-Andersen, Peter
Moscicki, Richard A.
Sahakian, Barbara
Quirion, Rémi
Krishnan, K. Ranga Rama
Race, Tim
author_sort Phillips, Anthony George
collection PubMed
description Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21(st) century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile, the rate of development of new CNS drugs has not increased for many years, despite unprecedented levels of investment. In response to this state of affairs, the Collegium Internationale Neuro-Psychopharmacologicum (CINP) convened a summit to discuss ways to reverse this disturbing trend through new partnerships to accelerate CNS drug discovery. The objectives of the Summit were to explore the issues affecting the value chain (i.e. the chain of activities or stakeholders that a company engages in/with to deliver a product to market) in brain research, thereby gaining insights from key stakeholders and developing actions to address unmet needs; to identify achievable objectives to address the issues; to develop action plans to bring about measurable improvements across the value chain and accelerate CNS drug discovery; and finally, to communicate recommendations to governments, the research and development community, and other relevant stakeholders. 1. Code of conduct dealing with conflict of interest issues, 2. Prevention, early diagnosis, and treatment, 3. Linking science and regulation, 4. Patient involvement in trial design, definition of endpoints, etc., 5. Novel trial design, 6. Reproduction and confirmation of data, 7. Update of intellectual property (IP) laws to facilitate repurposing and combination therapy (low priority), 8. Large-scale, global patient registries, 9. Editorials on nomenclature, biomarkers, and diagnostic tools, and 10. Public awareness, with brain disease advocates to attend G8 meetings and World Economic Forum (WEF) Annual meetings in Davos, Switzerland. In this context Professor Barbara Sahakian recently made a formal presentation at the World Economic Forum (see Barbara Sahakian Blog from April 11, 2014, at https://forumblog.org/people/barbara-sahakian/). Full details of the discussions that formed the bases for these actions are presented in the main body of this document.
format Online
Article
Text
id pubmed-4360252
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43602522015-09-01 Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care Phillips, Anthony George Hongaard-Andersen, Peter Moscicki, Richard A. Sahakian, Barbara Quirion, Rémi Krishnan, K. Ranga Rama Race, Tim Int J Neuropsychopharmacol Review Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21(st) century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile, the rate of development of new CNS drugs has not increased for many years, despite unprecedented levels of investment. In response to this state of affairs, the Collegium Internationale Neuro-Psychopharmacologicum (CINP) convened a summit to discuss ways to reverse this disturbing trend through new partnerships to accelerate CNS drug discovery. The objectives of the Summit were to explore the issues affecting the value chain (i.e. the chain of activities or stakeholders that a company engages in/with to deliver a product to market) in brain research, thereby gaining insights from key stakeholders and developing actions to address unmet needs; to identify achievable objectives to address the issues; to develop action plans to bring about measurable improvements across the value chain and accelerate CNS drug discovery; and finally, to communicate recommendations to governments, the research and development community, and other relevant stakeholders. 1. Code of conduct dealing with conflict of interest issues, 2. Prevention, early diagnosis, and treatment, 3. Linking science and regulation, 4. Patient involvement in trial design, definition of endpoints, etc., 5. Novel trial design, 6. Reproduction and confirmation of data, 7. Update of intellectual property (IP) laws to facilitate repurposing and combination therapy (low priority), 8. Large-scale, global patient registries, 9. Editorials on nomenclature, biomarkers, and diagnostic tools, and 10. Public awareness, with brain disease advocates to attend G8 meetings and World Economic Forum (WEF) Annual meetings in Davos, Switzerland. In this context Professor Barbara Sahakian recently made a formal presentation at the World Economic Forum (see Barbara Sahakian Blog from April 11, 2014, at https://forumblog.org/people/barbara-sahakian/). Full details of the discussions that formed the bases for these actions are presented in the main body of this document. Oxford University Press 2015-01-31 /pmc/articles/PMC4360252/ /pubmed/25542690 http://dx.doi.org/10.1093/ijnp/pyu100 Text en © The Author 2015. Published by Oxford University Press on behalf of CINP. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Phillips, Anthony George
Hongaard-Andersen, Peter
Moscicki, Richard A.
Sahakian, Barbara
Quirion, Rémi
Krishnan, K. Ranga Rama
Race, Tim
Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title_full Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title_fullStr Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title_full_unstemmed Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title_short Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care
title_sort proceedings of the 2013 cinp summit: innovative partnerships to accelerate cns drug discovery for improved patient care
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360252/
https://www.ncbi.nlm.nih.gov/pubmed/25542690
http://dx.doi.org/10.1093/ijnp/pyu100
work_keys_str_mv AT phillipsanthonygeorge proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT hongaardandersenpeter proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT moscickiricharda proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT sahakianbarbara proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT quirionremi proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT krishnankrangarama proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare
AT racetim proceedingsofthe2013cinpsummitinnovativepartnershipstoacceleratecnsdrugdiscoveryforimprovedpatientcare